¹Ýµð¾Ø·ç´Ï½º ÀÎÅͳݼ­Á¡

³×ºñ°ÔÀÌ¼Ç ½Ç½Ã°£ Àαâ Ã¥

    ·ù¸¶Æ¼½º Áúȯ Áø´Ü°ú Ä¡·á

    ·ù¸¶Æ¼½º Áúȯ Áø´Ü°ú Ä¡·á

    • ÀÌÃæ¿ø Àú
    • ¿ìÁÖ¹®È­»ç
    • 2016³â 09¿ù 09ÀÏ
    • Á¤°¡
      50,000¿ø
    • ÆÇ¸Å°¡
      45,000¿ø [10% ÇÒÀÎ]
    • °áÁ¦ ÇýÅÃ
      ¹«ÀÌÀÚ
    • Àû¸³±Ý
      2,500¿ø Àû¸³ [5%P]

      NAVER Pay °áÁ¦ ½Ã ³×À̹öÆäÀÌ Æ÷ÀÎÆ® 5% Àû¸³ ?

    • ¹è¼Û±¸ºÐ
      ¾÷ü¹è¼Û(¹ÝµðºÏ)
    • ¹è¼Û·á
      ¹«·á¹è¼Û
    • Ãâ°í¿¹Á¤ÀÏ

      Ãâ°í¿¹Á¤ÀÏ ¾È³»

      ¡Ø Ãâ°í¿¹Á¤ÀÏÀº µµ¼­ Àç°í»óȲ¿¡ µû¶ó º¯µ¿µÉ ¼ö ÀÖ½À´Ï´Ù.

      close

      2025³â 12¿ù 17ÀÏ(¼ö)

      ¡Ø Ãâ°í¿¹Á¤ÀÏÀº µµ¼­ Àç°í»óȲ¿¡ µû¶ó º¯µ¿µÉ ¼ö ÀÖ½À´Ï´Ù.

    ¼ö·®
    ȸ¿ø¸®ºä
    - [0]
    ISBN: 9788988583456 294ÂÊ 513g 151 x 210 (§®)

    Áö±Ý ÀÌÃ¥Àº

    ÀÌ ºÐ¾ßÀÇ º£½ºÆ®¼¿·¯

    ÀÌ Ã¥ÀÌ ¼ÓÇÑ ºÐ¾ß

    ÃâÆÇ»ç ¸®ºä

    [·ù¸¶Æ¼½º Áúȯ Áø´Ü°ú Ä¡·á/Diagnosis and Treatment of Rheumatic Diseases]
    20³â°£ ·ù¸¶Æ¼½º ºÐ°ú Àü¹®ÀÇ»ç·Î¼­ ·ù¸¶Æ¼½º ÁúȯÀ» Áø´ÜÇϰí Ä¡·áÇÑ °æÇèÀ» ¹ÙÅÁÀ¸·Î [·ù¸¶Æ¼½º Áúȯ Áø´Ü°ú Ä¡·á/Diagnosis and Treatment  of Rheumatic Diseases]¸¦ ÃâÆÇÇÏ¿´´Ù.
    ÀÌ Ã¥Àº ·ù¸¶Æ¼½º ÁúȯÀ» ÁÖ·Î Áø·áÇÏ´Â Àǻ縦 À§ÇÏ¿© °í¾ÈµÈ Áø´Ü ¹× Ä¡·á ÇÁ·Î±×·¥ÀÇ ¼³¸í¼­ÀÌ´Ù. ¼ö¸¹Àº ·ù¸¶Æ¼½º ÁúȯÀ» ÀÇ»ç °³ÀÎÀÇ °æÇè°ú Áö½Ä¿¡¼­ Áø´ÜÇÏ°í Æò°¡ÇÏ´Â ÁÖ°üÀû ´Ü°è¿¡¼­ ¹þ¾î³ª ±Ù°Å Áß½ÉÀÇ °´°üÀûÀÎ Áø´Ü, Áúº´È°¼ºµµ Æò°¡, ¹× Ä¡·á °¡À̵å¶óÀÎÀ» º¸¿©ÁÖ´Â ÇÁ·Î±×·¥ÀÌ´Ù. ÀÌ ÇÁ·Î±×·¥Àº 100Æí ÀÌ»óÀÇ ¿Ü±¹ ³í¹®À» ¿¬±¸ ºÐ¼®ÇÏ¿© ·ù¸¶Æ¼½º ÁúȯÀ» ½±°Ô Áø´ÜÇϰí Ä¡·áÇÏ°Ô °í¾ÈµÇ¾ú´Ù.  PCÇÁ·Î±×·¥À» ÀÌ¿ëÇÏ¿© ÁúȯÀ» Áø´ÜÇÏ°í Æò°¡ÇÏ´Â ÃÖÃÊÀÇ ÀÇÇÐ Áø´ÜÇÁ·Î±×·¥ÀÌ¸ç ·ù¸¶Æ¼½º ¾ËÆÄ°íÀÌ´Ù.
    °¡Á¤¿¡¼­³ª Áø·á½Ç °³ÀÎ PC¿¡¼­ ȯÀÚ°¡ È£¼ÒÇÏ´Â Áõ»óÀ̳ª ¡Èĸ¦ Ŭ¸¯Çϸé Áø´Ü °á°ú¸¦ ¾Ë ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ÀúÀå ¹× Ãâ·ÂÀÌ °¡´ÉÇÏ¿© Àå±â°£ ±â·Ï º¸°üÀÌ °¡´ÉÇÏ´Ù.
    ÀÌ ÇÁ·Î±×·¥¿¡´Â ÀÇÇÐ ±³°ú¼­¿Í ±ÇÀ§ ÀÖ´Â ·ù¸¶Æ¼½ºÇÐȸ ¹× ¿¬±¸±â°ü¿¡¼­ ÀÎÁ¤ÇÑ 27°¡Áö ·ù¸¶Æ¼½º ÁúȯµéÀ» Áø´Ü°ú Ä¡·á °¡À̵å¶óÀÎÀÌ ¼ö·ÏµÇ¾î ÀÖ´Ù. ÀÌ Ã¥°ú ÇÁ·Î±×·¥¿¡´Â ¿øº»ÀÎ ¿µ¾î¿Í Çѱ¹¾î°¡ µ¿½Ã¿¡ ¼ö·ÏµÇ¾î Àֱ⠶§¹®¿¡ ¼­·Î ºñ±³ ¹× ÀÌÇØ°¡ ¿ëÀÌÇÏ´Ù.
    ÇÁ·Î±×·¥ÀÌ ÀúÀåµÈ CD°¡ Ã¥¿¡ µ¿ºÀµÇ¾î ÀÖ°í CD ¾øÀÌ À¥»çÀÌÆ®·Îµµ ½±°Ô Á¢±ÙÇÏ¿© ¾÷µ¥ÀÌÆ®µÈ ÇÁ·Î±×·¥À» ÀÌ¿ëÇÒ ¼ö ÀÖ´Ù.


    ÀúÀÚ µå¸² 


    ÀúÀÚ ¼Ò°³

    ÀÌÃæ¿ø

    • ±¸ºÐ : Àú¼­
    • ±¹Àû : ´ëÇѹα¹
    • ºÐ·ù : °Ç°­/ÀÇÇÐ ÀúÀÚ
    • ÀαâÁö¼ö : 7

    ÀÌÃæ¿ø¿øÀåÀº 20³â°£ ·ù¸¶Æ¼½º Áúȯ Áø´Ü°ú Ä¡·á¿¡ Àü³äÇÏ´Â ´ëÇ¥ÀûÀÎ ·ù¸¶Æ¼½º Àü¹®ÀÇ»çÀÌ´Ù.
    ³»°ú Àü¹®Àǻ縦 Ãëµæ ÈÄ 1997³â Çѱ¹ ·ù¸¶Æ¼½º ÁúȯÀÇ ¼±µÎÀû ¿¬±¸ ¹× Áø·á ±â°üÀÎ ¿¬¼¼´ëÇб³ ½ÅÃ̼¼ºê¶õ½º º´¿ø ·ù¸¶Æ¼½º ³»°ú¿¡¼­ ÀüÀÓÀÇ °úÁ¤À» ½ÃÀÛÇÏ¿´°í 1998~1999³â µ¿¾È ¹Ì±¹ ¾Ù¶ó¹è¸¶ ÁÖ¸³´ëÇÐ º´¿ø ¸é¿ªÇÐ ¹× ·ù¸¶Æ¼½º ³»°ú¿¡¼­ ¿¬¼ö¸¦ ÇÏ¿´´Ù. ±Í±¹ ÈÄ Á¹¾÷ÇÑ ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ´ëÇпø¿¡¼­ ¹Ú»ç ÇÐÀ§¸¦ ¹Þ¾Ò´Ù. ħ·Êº´¿ø ·ù¸¶Æ¼½º ¼¾Å͸¦ °³¼ÒÇÏ¿© 14³â°£ ·ù¸¶Æ¼½º Áúȯ ȯÀÚ¸¦ Áø·áÇϰí Ä¡·áÇϴµ¥ ÃÖ¼±À» ´ÙÇÏ¿´´Ù. ±× µ¿¾ÈÀÇ ÀÓ»ó °æÇè°ú ¿¬±¸¸¦ ¹ÙÅÁÀ¸·Î ÇÏ¿© 48ÆíÀÇ ¿¬±¸ ³í¹®À» ±¹³»¿Ü Àú³Î¿¡ ¹ßÇ¥ ÇÏ¿´´Ù.
    1998³â ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿ì¼ö ³í¹®»óÀ» ½ÃÀÛÇÏ¿© ¿Ð·¹½º ¿ì¼ö ³í¹®»ó, ´ëÇѳ»°úÇÐȸ ¿ì¼ö ³í¹®»óÀ» ¼ö»ó ÇÏ¿´´Ù. ±× µ¿¾ÈÀÇ ¾÷ÀûÀ» ÀÎÁ¤ ¹Þ¾Æ 2009³âºÎÅÍ ¸¶¸£ÄûÁî ÈÄÁî ÈÄ ¹× International Health Professional of the Year 2012 ÀÎ¸í »çÀü¿¡ µîÀç µÇ¾ú´Ù.
    2014³âºÎÅÍ ÀÌÃæ¿ø´º¸¶³»°úÀÇ¿ø ¿øÀåÀ¸·Î ÀçÁ÷ ÁßÀÌ´Ù.

     

     

    ¸ñÂ÷

    ¸ñÂ÷
    1. Lists of rheumatic Diseases 14
    2. Diagnosis of Ankylosing spondylitis 16
    3. Diagnosis of Axial Spondyloarthritis 17
    4. Diagnosis of Peripheral Spondyloarthritis 18
    5. Disease activity of Ankylosing spondylitis
    5-1.Bath Ankylosing Spondyloarthritis Disease ActivityIndex (BASDAI) 19
    5-2.Ankylosing Spondylitis Disease Activity Score(ASDAS) 20
    5-3.Bath Ankylosing Spondylitis Functional Index(BASFI) 21
    5-4.Assessment in Ankylosing Spondylitis Improvement (ASAS) 22
    5-5.Bath Ankylosing Spondylitis Metrology Index (BASMI) 23
    5-6.Modified Stoke Ankylosing Spondylitis SpinaScore (mSASSS) 24
    5-7.Ankylosing Spondylitis Spinal MRI (ASspiMRI) Score 25
    6. Treatment of Ankylosing spondylitis (AS)
    6-1 2010 ASAS/EULAR recommendations for managementof AS 26
    6-2 2015 ACR/SAA/SPARTAN recommendation for treatmentof AS and non-radiographic axial spondyloarthritis 28
    7. Diagnosis of Antiphospholipid Syndrome 30
    8. Diagnosis of Adult Onset Still¡¯s Disease
    8-1. Cush Criteria for classification of Adult OnseStill¡¯s Disease 32
    8-2. Yamaguchi Criteria for classification of Adult OnsetStill¡¯s Disease 33
    9. Diagnosis of Fibromyalgia 35
    10. Disease activity of Fibromyalgia 36
    11. Treatment of Fibromyalgia
    2016 EULAR recommendation for managementof fibromyalgia 38
    12. Diagnosis of Gout 40
    13. Disease activity of Gout
    13-1.Disease severity of acute gout arthritis (AGA) 41
    13-2.Disease severity of chronic tophaceous goutarthropathy 42
    14. Treatment of Gout
    2012 ACR guidelines for management of Gout 43
    15. Diagnosis of Juvenile Idiopathic Arthritis 52
    16. Treatment of Juvenile Idiopathic Arthritis
    2013 ACR recommendation for treatment of JuvenileIdiopathic Arthritis 53
    17. Diagnosis of knee Osteoarthritis 55
    18. Western Ontario McMaster Universities Arthritis Index(WOMAC) Index 56
    19. Treatment of knee Osteoarthritis
    19-1. 2012 ACR recommendation for managementof knee Osteoarthritis 57
    19-2. 2003 EULAR recommendation for managementof knee Osteoarthritis 58
    20. Diagnosis of hand Osteoarthritis 59
    21. Treatment of hand Osteoarthritis2012 ACR recommendation for management ofhand Osteoarthritis 60
    22. Diagnosis of Polymyositis and Dermatomyositis 62
    23. Diagnosis of Psoriatic arthritis 64
    24. Treatment of Psoriatic arthritis2015 EULAR recommendations for management ofPsoriatic arthritis 65
    25. Diagnosis of Reactive arthritis 68
    26. Diagnosis of CPPD arthritis (Pseudogout) 70
    27. Treatment of CPPD arthritis (Pseudogout)
    2011 EULAR recommendations for management ofCPPD arthritis (Pseudogout) 71
    28. Diagnosis of Polymyalgia Rheumatica 73
    29. Treatment of Polymyalgia Rheumatica2015 ACR/EULAR recommendations for managementof Polymyalgia Rheumatica 74
    30. Diagnosis of Rheumatic Fever 78
    31. Diagnosis of Rheumatoid Arthritis 80
    32. Disease activity of Rheumatoid Arthritis
    32-1. Disease Activity Score (DAS) 28 81
    32-2. Simplified Disease Activity Index (SDAI) 82
    32-3. Health Assessment Questionnaire (HAQ) 83
    32-4. Patient Activity Scale (PAS) 84
    32-5. American College of Rheumatology Response
    (ACR20, ACR50, ACR70) 85
    32-6. Remission criteria of Rheumatoid Arthritis 86
    33. Treatment of Rheumatoid Arthritis 87
    33-1. 2016 EULAR recommendation for managementofRheumatoid Arthritis 88
    33-2. 2015 ACR guideline for treatment ofRheumatoidArthritis 89
    34. Diagnosis of Relapsing Polychondritis 93
    35. Diagnosis of Systemic Sclerosis 95
    36. Disease activity of Systemic Sclerosis
    36-1. Modified Rodnan¡¯s Skin Score 96
    36-2. EUSTAR Systemic Sclerosis Activity Score 97
    37. Treatment of Systemic Sclerosis
    2008 EULAR recommendations for management ofSystemic Sclerosis 98
    38. Diagnosis of Mixed Connective Tissue Disease 100
    39. Diagnosis of Systemic Lupus Erythematosus
    39-1. 1997 Classification criteria of Systemic LupusErythematosus 102
    39-2. SLICC Classification criteria of Systemic LupusErythematosus 103
    40. Disease activity of Systemic Lupus Erythematosus 104
    41. Damage index of Systemic Lupus Erythematosus

    ¹è¼Û ½Ã À¯ÀÇ»çÇ×

    - ¹Ýµð¾Ø·ç´Ï½º¿¡¼­ ±¸¸ÅÇϽеµ¼­´Â ¹°·ù ´ëÇà À§Å¹¾÷ü ¿õÁø ºÏ¼¾À» ÅëÇØ ¹è¼ÛµË´Ï´Ù.
     (¹è¼Û Æ÷Àå¿¡ "¿õÁø ºÏ¼¾"À¸·Î Ç¥±âµÉ ¼ö ÀÖ½À´Ï´Ù.)

    - ±¸¸ÅÇÑ »óǰÀÇ Ç°Áú°ú ¹è¼Û °ü·Ã ¹®ÀÇ´Â ¹Ýµð¾Ø·ç´Ï½º·Î ¹®ÀÇ ¹Ù¶ø´Ï´Ù.

    - õÀçÁöº¯ ¹× Åùè»çÀÇ »çÁ¤¿¡ µû¶ó ¹è¼ÛÀÌ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.

    - °áÁ¦(ÀÔ±Ý) ¿Ï·á ÈÄ ÃâÆÇ»ç ¹× À¯Åë»çÀÇ »çÁ¤À¸·Î ǰÀý ¶Ç´Â ÀýÆÇ µÇ¾î »óǰ ±¸ÀÔÀÌ ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù. (º°µµ ¾È³» ¿¹Á¤)

    - µµ¼­»ê°£Áö¿ªÀÇ °æ¿ì Ãß°¡ ¹è¼Ûºñ°¡ ¹ß»ýµÉ ¼ö ÀÖ½À´Ï´Ù.

    ¹Ýǰ/±³È¯

    »óǰ ¼³¸í¿¡ ¹Ýǰ/ ±³È¯ °ü·ÃÇÑ ¾È³»°¡ ÀÖ´Â °æ¿ì ±× ³»¿ëÀ» ¿ì¼±À¸·Î ÇÕ´Ï´Ù. (¾÷ü »çÁ¤¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù)

    ¹Ýǰ/±³È¯

    ¹Ýǰ/±³È¯
    ¹Ýǰ/±³È¯ ¹æ¹ý Ȩ > °í°´¼¾ÅÍ > ÀÚÁÖã´ÂÁú¹® ¡°¹Ýǰ/±³È¯/ȯºÒ¡± ¾È³» Âü°í ¶Ç´Â 1:1»ó´ã°Ô½ÃÆÇ
    ¹Ýǰ/±³È¯ °¡´É ±â°£ ¹Ýǰ,±³È¯Àº ¹è¼Û¿Ï·á ÈÄ 7ÀÏ À̳», »óǰÀÇ °áÇÔ ¹× °è¾à³»¿ë°ú ´Ù¸¦ °æ¿ì ¹®Á¦¹ß°ß ÈÄ 30ÀÏ À̳»¿¡ ½Åû°¡´É
    ¹Ýǰ/±³È¯ ºñ¿ë º¯½É ȤÀº ±¸¸ÅÂø¿ÀÀÇ °æ¿ì¿¡¸¸ ¹Ý¼Û·á °í°´ ºÎ´ã(º°µµ ÁöÁ¤ Åùè»ç ¾øÀ½)
    ¹Ýǰ/±³È¯ ºÒ°¡ »çÀ¯
    • ¼ÒºñÀÚÀÇ Ã¥ÀÓ »çÀ¯·Î »óǰ µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
    • ¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óǰ µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
    • º¹Á¦°¡ °¡´ÉÇÑ »óǰ µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì : ¿¹)¸¸È­Ã¥, ÀâÁö, È­º¸Áý µî
    • ½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆÇ¸Å°¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
    • ÀüÀÚ»ó°Å·¡µî¿¡¼­ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì
    • ÇØ¿ÜÁÖ¹® »óǰ(ÇØ¿Ü ¿ø¼­)ÀÇ °æ¿ì(ÆÄº»/ÈѼÕ/¿À¹ß¼Û »óǰÀ» Á¦¿Ü)
    ¼ÒºñÀÚ ÇÇÇØº¸»ó
    ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó
    • »óǰÀÇ ºÒ·®¿¡ ÀÇÇÑ ¹Ýǰ, ±³È¯, A/S, ȯºÒ, ǰÁúº¸Áõ ¹× ÇÇÇØº¸»ó µî¿¡ °üÇÑ »çÇ×Àº
      ¼ÒºñÀÚ ºÐÀïÇØ°á ±âÁØ(°øÁ¤°Å·¡À§¿øÈ¸°í½Ã)¿¡ ÁØÇÏ¿© 󸮵Ê
    • ´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ
      ¼ÒºñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ
    ¹Ýǰ/±³È¯ ÁÖ¼Ò °æ±âµµ ÆÄÁֽà ¹®¹ß·Î 77, ¿õÁøºÏ¼¾(¹Ýµð¾Ø·ç´Ï½º)
    • ȸ»ç¸í : (ÁÖ)¼­¿ï¹®°í
    • ´ëÇ¥ÀÌ»ç : ±èÈ«±¸
    • °³ÀÎÁ¤º¸ º¸È£Ã¥ÀÓÀÚ : ±èÈ«±¸
    • E-mail : bandi_cs@bnl.co.kr
    • ¼ÒÀçÁö : (06168) ¼­¿ï °­³²±¸ »ï¼º·Î 96±æ 6
    • »ç¾÷ÀÚ µî·Ï¹øÈ£ : 120-81-02543
    • Åë½ÅÆÇ¸Å¾÷ ½Å°í¹øÈ£ : Á¦2023-¼­¿ï°­³²-03728È£
    • ¹°·ù¼¾ÅÍ : (10881) °æ±âµµ ÆÄÁֽà ¹®¹ß·Î 77 ¹Ýµð¾Ø·ç´Ï½º
    copyright (c) 2016 BANDI&LUNI'S All Rights Reserved